The nanoparticles are designed to deliver a therapeutic gene to the patient’s eye through a single intravenous injection, rather than through a series of injections given directly into the eye.
Dr. Ambati and his research team are currently testing the treatment on mice.
More Articles on Ophthalmology:
Dr. Gholman Peyman Joins Insite Vision
Durrie Vision Helps Develop SBK LASIK
National Eye Institute Funds $6.2M Macular Degeneration Study
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
